During the past decade, OncoResearch Lerchenfeld GmbH conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 8 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 4 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "OncoResearch Lerchenfeld GmbH" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Celgene" with 3 trials sponsored, "German CLL Study Group" with 3 trials sponsored, "Helsinn Healthcare SA" with 3 trials sponsored and "Advancell - Advanced In Vitro Cell Technologies, S.A." with 3 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "OncoResearch Lerchenfeld GmbH" #1 collaborator was "Cancer Trials Ireland" with 2 trials as a collaborator, "Nordic CLL Study Group (NCLLSG)" with 2 trials as a collaborator, "Parexel" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "OncoResearch Lerchenfeld GmbH" are "Chemotherapy-Induced Nausea and Vomiting" (3 trials), "Myelodysplastic Syndromes" (3 trials), "Anemia" (2 trials), "Breast Cancer" (2 trials) and "Chronic Lymphocytic Leukemia" (2 trials). Many other conditions were trialed in "OncoResearch Lerchenfeld GmbH" in a lesser frequency.

Most popular intervention types in "OncoResearch Lerchenfeld GmbH" are "Drug" (18 trials), "Biological" (3 trials), "Other" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Obinutuzumab" (4 trials), "Bendamustine" (3 trials), "Cyclophosphamide" (3 trials), "Dexamethasone" (3 trials) and "Ibrutinib" (3 trials). Other intervention names were less common.

The vast majority of trials in "OncoResearch Lerchenfeld GmbH" are 20 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "OncoResearch Lerchenfeld GmbH". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in OncoResearch Lerchenfeld GmbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in OncoResearch Lerchenfeld GmbH, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".